Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The New Ophthalmic Drug Players

This article was originally published in Start Up

Executive Summary

Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind. This interest is fueled by a stable pool of acquirers and the ability to in-license innovative, clinically validated compounds, providing VCs with a jump start to a potential exit.
Advertisement

Related Content

ONL Therapeutics LLC
Xcovery Vision LLC
Start-Up Previews (10/2011)
Imagen Biotech Inc.
KalVista Pharmaceuticals Ltd.
A Bad Day for Lucentis
START-UP's 2011 Life Science Venture Capital Survey: Biopharmaceutical Investors Let Some Sunshine In
Eyeing New Drugs For Glaucoma
Venture Eyes Ophthalmology--And Likes What It Sees
Biotechs Eye Macular Degeneration

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092195

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel